Patients previously treated with r-HuEPO require higher darbepoetin doses than naive patients do, most likely due to a longer period of chronic renal failure, dialysis status, and reduced level of residual erythropoietin secretion, exacerbated iron loss and accumulation of erythropoiesis inhibitors. The gene discussed is EPO; the disease is chronic kidney disease.